Knockdown of Efp by DNA-modified small interfering RNA inhibits breast cancer cell proliferation and in vivo tumor growth

Cancer Gene Therapy

Volumn 17, Issue 9, 2010, Pages 624-632

  Ueyama, K ^a,b   Ikeda, K ^a   Sato, W ^a   Nakasato, N ^a   Horie Inoue, K K ^a   Takeda, S ^b   Inoue, S ^a,c  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

breast cancer; DNA modified siRNA; Efp; siRNA

Indexed keywords

BETA ACTIN; SMALL INTERFERING RNA; STRATIFIN;

ALGORITHM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GENE THERAPY; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL STRAIN MCF 7; CHIMERA; CONTROLLED STUDY; DNA MODIFICATION; EFP GENE; ESTROGEN RESPONSIVE ELEMENT; FEMALE; GENE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; UBIQUITIN-PROTEIN LIGASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MAMMALIA; MUS;

EID: 77955917769     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.19     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354: 270-282.
3. Inoue S, Orimo A, Hosoi T, Kondo S, Toyoshima H, Kondo T et al. Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. Proc Natl Acad Sci USA 1993; 90: 11117-11121.
4. Ikeda K, Orimo A, Higashi Y, Muramatsu M, Inoue S. Efp as a primary estrogen-responsive gene in human breast cancer. FEBS Lett 2000; 472: 9-13.
5. Orimo A, Inoue S, Ikeda K, Noji S, Muramatsu M. Molecular cloning, structure, and expression of mouse estrogen-responsive finger protein Efp. Co-localizationwith estrogen receptor mRNA in target organs. J Biol Chem 1995; 270: 24406-24413.
6. Orimo A, Inoue S, Minowa O, Tominaga N, Tomioka Y, Sato M et al. Underdeveloped uterus and reduced estrogen responsiveness in mice with disruption of the estrogen-responsive finger protein gene, which is a direct target of estrogen receptor a. Proc Natl Acad Sci USA 1999; 96: 12027-12032.
7. Suzuki T, Urano T, Tsukui T, Horie-Inoue K, Moriya T, Ishida T et al. Estrogen-responsive finger protein as a new potential biomarker for breast cancer. Clin Cancer Res 2005; 11: 6148-6154.
8. Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M et al. Efp targets 14-3-3s for proteolysis and promotes breast tumour growth. Nature 2002; 417: 871-875.
9. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007; 59: 75-86.
10. Aigner A. Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl Microbiol Biotechnol 2007; 76: 9-21.
11. Uprichard SL. The therapeutic potential of RNA interference. FEBS Lett 2005; 579: 5996-6007.
12. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007; 8: 173-184.
13. Fedorov Y, Anderson EM, Birmingham A, Reynolds A, Karpilow J, Robinson K et al. Off-target effects by siRNA can induce toxic phenotype. RNA 2006; 12: 1188-1196.
14. Judge A, MacLachlan I. Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 2008; 19: 111-124.
15. Ui-Tei K, Naito Y, Zenno S, Nishi K, Yamato K, Takahashi F et al. Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res 2008; 36: 2136-2151.
16. Naito Y, Yamada T, Matsumiya T, Ui-Tei K, Saigo K, Morishita S. dsCheck: highly sensitive off-target search software for double-stranded RNA-mediated RNA interference. Nucleic Acids Res 2005; 33(Web Server issue): W589-W591.
17. Naito Y, Yamada T, Ui-Tei K, Morishita S, Saigo K. siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference. Nucleic Acids Res 2004; 32(Web Server issue): W124-W129.
18. Horie-Inoue K, Takayama K, Bono HU, Ouchi Y, Okazaki Y, Inoue S. Identification of novel steroid target genes through the combination of bioinformatics and functional analysis of hormone response elements. Biochem Biophys Res Commun 2006; 339: 99-106.
19. Aleku M, Schulz P, Keil O, Santel A, Schaeper U, Dieckhoff B et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 2008; 68: 9788-9798.
20. Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y et al. 3UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 2006; 3: 199-204.
21. Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 2006; 13: 494-505.
22. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999; 401: 616-620.
23. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 2007; 446: 916-920.
24. Nakajima A, Maruyama S, Bohgaki M, Miyajima N, Tsukiyama T, Sakuragi N et al. Ligand-dependent transcription of estrogen receptor alpha is mediated by the ubiquitin ligase EFP. Biochem Biophys Res Commun 2007; 357: 245-251.
25. Lee MH, Lozano G. Regulation of the p53-MDM2 pathway by 14-3-3s and other proteins. Semin Cancer Biol 2006; 16: 225-234.
26. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2: 101-112.
27. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1-22.
28. Jordan VC. Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 1993; 110: 507-517.
29. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281: 2189-2197.
30. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, et al., Arimidex Writing Committee; Investigators Committee Members. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92: 2247-2258.
31. Hurvitz SA, Pietras RJ. Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer 2008; 113: 2385-2397.
32. Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 2008; 8: 307.